In Vivo Gene Therapy: How It Works, Results and What to Expect

In vivo gene therapy delivers a working gene, gene-editing instructions, or another genetic treatment directly into a person’s body so it can reach selected cells. It is used for a limited but growing range of inherited and acquired conditions, with eligibility, results, and monitoring depending on the specific disease and therapy.

Overview: What is in vivo gene therapy and how does it work?

In vivo gene therapy is a form of genetic medicine in which therapeutic genetic material is delivered directly into the body. The aim may be to provide a functioning copy of a gene, help cells produce a needed protein, silence a harmful gene, or make a precise genetic change. The treatment is designed to reach particular cells or organs rather than changing every cell in the body.

Many in vivo treatments use a modified virus, called a vector, as a delivery vehicle. The vector is engineered so it cannot cause the original viral illness. It carries genetic instructions into target cells, where those instructions can help the cells make a protein that is missing or not working properly. Other approaches use nonviral carriers, such as lipid nanoparticles, particularly when a temporary genetic effect is intended.

In vivo therapy differs from ex vivo gene therapy. In ex vivo treatment, clinicians collect a patient’s cells, modify them in a laboratory, test or prepare them, and then return them to the body. In vivo therapy avoids collecting and reinfusing cells, but it requires a delivery method that can safely reach the right tissue within the body.

Can you give me an example of in vivo therapy?

An established example is gene replacement therapy for certain inherited retinal diseases. A treatment can be injected into the eye to deliver a working copy of a gene to retinal cells, helping those cells carry out an essential function involved in vision. This is an in vivo approach because the genetic material is delivered directly to tissue within the person’s body.

Other in vivo gene therapies are used for selected inherited neuromuscular disorders, bleeding disorders, and metabolic diseases. Depending on the therapy, the genetic material may be delivered by a one-time intravenous infusion, injected into the fluid around the spinal cord, placed into an eye, or delivered into another target area.

Not every genetic condition has a gene therapy, and a treatment available for one gene change may not be appropriate for another. A specialist team confirms the diagnosis, genetic variant, disease stage, and organ health before discussing whether a particular therapy may be suitable.

Who may be a candidate for in vivo gene therapy?

Candidacy begins with a clear diagnosis. For inherited conditions, this usually includes genetic testing that identifies the disease-causing change and confirms that it matches the condition targeted by a specific therapy. Clinical assessment also considers symptoms, disease severity, prior treatments, and whether treatment is expected to benefit the person at their current stage of disease.

Specialists review factors that can affect safety and effectiveness. These may include liver, kidney, heart, and immune-system health; current infections; pregnancy status where relevant; and prior exposure to a vector. Some people have antibodies that may prevent a viral vector from reaching its intended cells effectively, so blood testing may be needed before treatment.

Eligibility criteria differ between therapies and can change as evidence develops. A multidisciplinary team may include geneticists, disease-specific physicians, pharmacists, laboratory specialists, nurses, and rehabilitation professionals. Genetic counselling can help individuals and families understand inheritance, testing results, uncertainties, and the implications of treatment decisions.

• Confirmed diagnosis and, where relevant, an eligible genetic variant
• Clinical features that match the treatment indication
• Suitable organ function and no contraindications identified during assessment
• Ability to attend planned monitoring visits and laboratory testing

What happens during an in vivo gene therapy procedure?

The process usually starts well before the treatment day. The care team reviews medical history, medicines, vaccinations, previous treatments, imaging when needed, and laboratory results. They explain the anticipated benefits and limits of therapy, possible short- and long-term risks, alternatives, and the follow-up plan. Some therapies require medicines before or after administration to reduce immune reactions.

On the day of treatment, the route depends on the medicine and target tissue. An intravenous therapy is commonly delivered through a vein over a planned period in a hospital or specialist infusion setting. Other therapies may be administered by a surgeon or specialist using local or general anaesthesia, such as an injection into the eye or another carefully selected site.

During and immediately after treatment, healthcare professionals monitor vital signs and watch for infusion reactions or other early effects. Blood tests may be repeated to assess organ function and inflammation. The administration itself may take hours or less, but observation and the wider treatment visit can take longer.

In vivo gene therapy is highly condition-specific. Patients should not stop prescribed medicines or assume that a genetic treatment will immediately replace all supportive care. The clinical team provides an individualized plan for ongoing medications, therapy, rehabilitation, and routine disease management.

Benefits, results and recovery timeline

The potential benefit of in vivo gene therapy is that a single administration may provide genetic instructions that continue working in target cells for a prolonged period. For some conditions, this can improve a missing biological function, reduce symptoms or complications, slow progression, or reduce the need for certain ongoing treatments. However, it is not always a cure, and it may not reverse damage that occurred before treatment.

Results vary according to the condition, the therapy, age and health at treatment, degree of existing organ damage, immune response, and how well the treatment reaches the intended cells. Some effects may be assessed within days or weeks through laboratory changes, while meaningful functional changes can take months. For progressive conditions, a key treatment goal may be stabilization or slower worsening rather than a visible immediate improvement.

Recovery after an infusion or procedure is often brief, but monitoring continues for months or years. Follow-up may include physical examinations, blood tests, imaging, functional assessments, and disease-specific measurements. Patients may need to avoid certain activities temporarily, particularly after a surgical delivery procedure or if laboratory tests are abnormal.

Long-term follow-up is an important part of gene therapy care. It helps clinicians identify delayed effects, understand durability, and adjust supportive treatment. The team will explain which symptoms should prompt an urgent call and how frequently appointments are likely to be needed.

Are there side effects to gene therapy?

Yes. Side effects are possible with in vivo gene therapy, although the type and likelihood depend on the specific product, delivery method, dose, and patient’s health. Early reactions can include fever, chills, headache, nausea, tiredness, muscle aches, or changes in blood pressure during or shortly after an infusion. These are often related to immune-system activation and are monitored closely.

Some therapies can affect the liver, blood counts, kidneys, heart, or nervous system. For example, elevated liver enzymes may occur after certain vector-based treatments, which is why regular blood testing is often required. Local procedures can also have site-specific risks, such as pain, inflammation, infection, bleeding, or effects on the treated organ.

There are also uncertainties because gene therapies are relatively new and their long-term effects continue to be studied. Some genetic instructions may remain active for a long time, while others may not persist. The possibility of a reduced response, delayed adverse effects, or the need for continued conventional treatment should be discussed openly before treatment.

Patients should promptly report new or worsening symptoms after therapy, especially fever, breathing difficulty, chest pain, severe headache, unusual bruising or bleeding, yellowing of the skin or eyes, severe weakness, or reduced urine output. The treating team provides condition- and product-specific safety instructions.

What is the success rate of gene therapy?

There is no single success rate for gene therapy. Results cannot be meaningfully summarized with one percentage because gene therapies treat different diseases, use different delivery systems, and measure success in different ways. In one condition, success may mean a measurable protein level; in another, it may mean improved vision, fewer disease complications, delayed progression, or greater independence in daily life.

Clinical trial findings and regulatory information can describe outcomes for a particular approved therapy, but these results may not predict an individual person’s experience. Trial participants are selected using specific criteria and are monitored in specialized settings. Real-world outcomes may differ because of disease severity, age, coexisting conditions, immune factors, and treatment timing.

Before deciding, patients can ask their specialist what outcomes were measured in studies, how long participants were followed, what is known about durability, and what outcomes are realistic in their situation. A balanced discussion includes potential improvements as well as the possibility of limited benefit or no meaningful response.

Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals support international patients who need evaluation and treatment planning for complex genetic and rare conditions, with follow-up coordinated around the individual therapy and diagnosis.

When to seek medical care

People who have symptoms suggesting an inherited condition, a known family history of a genetic disorder, or a confirmed genetic diagnosis should seek assessment from a qualified physician or clinical genetics service. Early evaluation may clarify the cause of symptoms, identify monitoring needs, and determine whether disease-specific treatments or clinical trials may be relevant.

Anyone receiving or preparing for gene therapy should contact the treating team if they develop new symptoms, have an infection, start a new medicine, or are considering pregnancy. After treatment, urgent medical care is appropriate for severe allergic symptoms, difficulty breathing, chest pain, fainting, rapidly worsening weakness, confusion, severe abdominal pain, or other serious or rapidly progressing symptoms.

Gene therapy decisions are complex and should be made with a specialist team rather than through online information alone. A second opinion from an experienced genetics or disease-specific center can be helpful when considering eligibility, potential benefits, risks, and long-term monitoring.

Frequently asked questions

What is the difference between in vivo and ex vivo gene therapy?

In vivo gene therapy delivers genetic material directly into the body, aiming to reach selected cells or tissues. Ex vivo gene therapy involves collecting cells from the patient, modifying them in a laboratory, and returning them to the body. The most appropriate approach depends on the disease, target cells, and available treatment.

Is in vivo gene therapy permanent?

Its effects may be long-lasting, but permanence depends on the therapy, the cells targeted, and the delivery system. Some treatments are intended to provide durable genetic instructions in long-lived cells, while others may have a more temporary effect. Long-term follow-up is needed to understand how long benefits last for each treatment.

Can in vivo gene therapy change genes passed to children?

Approved in vivo gene therapies are designed to treat body cells, known as somatic cells. They are not intended to alter eggs, sperm, or genes passed to future children. Genetic counselling may still be useful because the underlying inherited condition can remain relevant to family planning.

How long does an in vivo gene therapy appointment take?

The administration time varies by treatment and route of delivery. An intravenous infusion may take part of a day, while a procedure involving an injection into a specific organ may require preparation, anaesthesia, and recovery time. Observation after treatment and follow-up blood testing are often part of the care plan.

Will gene therapy replace all other treatment?

Not necessarily. Some patients may still need medications, rehabilitation, surgery, monitoring, or other supportive care after gene therapy. The care team will explain which treatments should continue and whether any changes are appropriate over time.

Is gene therapy only for inherited disorders?

Many current gene therapies target inherited disorders, but genetic approaches are also being developed or used in areas such as cancer and infectious disease. The term covers several technologies, and availability depends on the condition, region, regulatory approval, and clinical suitability.

References

• U.S. Food and Drug Administration
• European Medicines Agency
• National Human Genome Research Institute
• World Health Organization
• American Society of Gene and Cell Therapy

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.